High-Tech Biotechnology fighting cancer
Continuous innovation, strong customer focus and creative problem solving have made ScheBo®• Biotech AG a worldwide leading manufacturer of unique products.
ScheBo® • Biotech AG
- worldwide distribution network
- exclusive and superior technologies and products
- innovative and unique clinical diagnostic products
- international research network
The high sensitivity (c.80%) and high specificity (>90%) of the M2-PK stool test for colorectal cancer screening and detection, plus benefits for patients, laboratories and doctors, was presented at Focus 2010
Focusing on results with faecal pancreatic elastase and faecal lactoferrin from clinical studies conducted at the Royal Hallamshire Hospital in Sheffield, Dr David Sanders discusses the clinical value of faecal diagnostic assays
Polish scientists publish a study of the sensitivity and specificity of the Pancreas Elastase 1 Quick test in comparison to the ELISA test in the “Journal of Cystic Fibrosis”.
Malaysian scientists publish the very latest results on colorectal cancer screening using the M2-PK test in the renowned journal “PLOS ONE”.
Korean Scientists have published the very newest data on the M2-PK test in the renowned specialist journal ‚Gut and Liver‘.
The stool test for the fast and reliable diagnosis/ exclusion of Exocrine Pancreatic Insufficiency in dogs is
… now also available as a rapid test